Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
CLAFORAN (cefotaxime sodium) is a third-generation cephalosporin antibiotic administered by injection for treating serious bacterial infections including septicemia, meningitis, and other gram-positive and gram-negative infections. It works by inhibiting bacterial cell wall synthesis, bactericidally eliminating susceptible pathogens. This injectable antibiotic has been a cornerstone therapy for acute care settings since approval.
As a mature injectable antibiotic approaching loss of exclusivity, commercial teams face declining revenues and minimal expansion opportunities; expect smaller, defensive team structures focused on market consolidation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CLAFORAN positions you in acute care/hospital infectious disease – a stable but mature franchise with limited growth trajectory. Career progression depends on territory management efficiency, formulary relationships, and defensive competitive tactics rather than innovation or market expansion.
Worked on CLAFORAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.